Clinical worsening in trials of pulmonary arterial hypertension: results and implications

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Current opinion in pulmonary medicine

• Publication date

  2010-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01.mcp.0000370206.61003.7ePMID 20375660
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry.

  2010cited by this paper
• Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era

  2010cited by this paper
• Tadalafil Therapy for Pulmonary Arterial Hypertension

  2009cited by this paper
• A meta-analysis of randomized controlled trials in pulmonary arterial hypertension

  2008cited by this paper
• Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2

  2008cited by this paper
• Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.

  2008cited by this paper
• Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial.

  2008cited by this paper
• CORRELATION OF WHO FUNCTIONAL CLASS AND INDICES OF DISEASE SEVERITY IN IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION: INSIGHTS FROM EARLY, BREATHE-1 AND 351 STUDIES

  2006cited by this paper
• Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.

  2006cited by this paper
• Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.

  2006cited by this paper
• Pulmonary arterial hypertension.

  2006cited by this paper
• Pulmonary arterial hypertension in France: results from a national registry.

  2006cited by this paper
• Sildenafil citrate therapy for pulmonary arterial hypertension.

  2005cited by this paper
• End points and clinical trial design in pulmonary arterial hypertension.

  2004cited by this paper
• Sitaxsentan therapy for pulmonary arterial hypertension.

  2004cited by this paper
• Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

  2002cited by this paper
• BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION

  2002cited by this paper
• ATS statement: guidelines for the six-minute walk test.

  2002cited by this paper
• Bosentan therapy for pulmonary arterial hypertension.

  2002cited by this paper
• Inhaled iloprost for severe pulmonary hypertension.

  2002cited by this paper
• Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.

  2001cited by this paper
• Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.

  2000cited by this paper
• Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease

  2000cited by this paper
• A COMPARISON OF CONTINUOUS INTRAVENOUS EPOPROSTENOL ( PROSTACYCLIN ) WITH CONVENTIONAL THERAPY FOR PRIMARY PULMONARY HYPERTENSION

  2000cited by this paper
• A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.

  1996cited by this paper
• Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial.

  1990cited by this paper
• Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol): Results of a Randomized Trial

  1990cited by this paper

• Association of risk assessment at diagnosis with healthcare resource utilization and health‐related quality of life outcomes in pulmonary arterial hypertension

  2024cites this paper
• Effect of ambrisentan in patients with systemic sclerosis and mild pulmonary arterial hypertension: long-term follow-up data from EDITA study

  2024cites this paper
• Antagonistas de los receptores de la endotelina

  2023cites this paper
• Real‐world treatment patterns, healthcare resource utilization, and cost among adults with pulmonary arterial hypertension in the United States

  2022influential citation
• Riociguat for Sarcoidosis Associated Pulmonary Hypertension: Results of a One Year Double Blind, Placebo Controlled Trial.

  2021cites this paper
• Contemporary Pharmacotherapeutic Approach in Pulmonary Arterial Hypertension.

  2021cites this paper
• Comparative effectiveness of oral prostacyclin pathway drugs on hospitalization in patients with pulmonary hypertension in the United States: a retrospective database analysis

  2020cites this paper
• Medication adherence, hospitalization, and healthcare resource utilization and costs in patients with pulmonary arterial hypertension treated with endothelin receptor antagonists or phosphodiesterase type-5 inhibitors

  2020cites this paper
• Prognostic Value of Risk Assessment Tools for Patients with Pulmonary Arterial Hypertension in WHO Functional Class II: A Post Hoc Analysis of the EARLY Trial

  2020cites this paper
• Burden of pulmonary hypertension in patients with portal hypertension in the United States: a retrospective database study

  2020cites this paper
• Cardiac-MRI Predicts Clinical Worsening and Mortality in Pulmonary Arterial Hypertension

  2020cites this paper
• Meaningful and feasible composite clinical worsening definitions in paediatric pulmonary arterial hypertension: An analysis of the TOPP registry.

  2019cites this paper
• PH Professional Network: Bridging the Gap: A Multidisciplinary Approach to Transitions of Care

  2019cites this paper
• National trends and outcomes of hospitalizations for pulmonary hypertension in Spain (2001-2014).

  2018cites this paper
• Successful treatment of late-onset pulmonary hypertension after atrial septal defect operation with macitentan: Our center experience

  2018cites this paper
• Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial

  2017cites this paper
• Prognostic factors, treatment goals and clinical endpoints in pediatric pulmonary arterial hypertension

  2017cites this paper
• University of Groningen Prognostic factors , treatment goals and clinical endpoints in pediatric pulmonary arterial hypertension

  2017cites this paper
• Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension

  2017cites this paper
• The Modified Borg Dyspnea Scale does not predict hospitalization in pulmonary arterial hypertension

  2017cites this paper
• A simple hemodynamic parameter to predict clinical worsening in pulmonary arterial hypertension

  2017cites this paper
• Efficacy and Safety of a Novel Endothelin Receptor Antagonist, Macitentan, in Japanese Patients With Pulmonary Arterial Hypertension.

  2016cites this paper
• Características farmacológicas diferenciales del macitentan y resumen del ensayo clínico SERAPHIN

  2016cites this paper
• Exercise training improves peak oxygen consumption and haemodynamics in patients with severe pulmonary arterial hypertension and inoperable chronic thrombo-embolic pulmonary hypertension: a prospective, randomized, controlled trial

  2015cites this paper
• Early Decline in Six-Minute Walk Distance from the Time of Diagnosis Predicts Clinical Worsening in Pulmonary Arterial Hypertension

  2015cites this paper
• Characterizing pulmonary hypertension-related hospitalization costs among Medicare Advantage or commercially insured patients with pulmonary arterial hypertension: a retrospective database study.

  2015cites this paper
• Effect of macitentan on hospitalizations: results from the SERAPHIN trial.

  2015cites this paper
• Clinical Worsening as Composite Study End Point in Pediatric Pulmonary Arterial Hypertension.

  2015cites this paper
• Hemodynamic, Functional, and Clinical Responses to Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension of Different Causes

  2015cites this paper
• Pulmonary hypertension trials: how can we do better?

  2015cites this paper
• Macitentan for the treatment of pulmonary arterial hypertension.

  2014cites this paper
• Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension

  2014cites this paper
• Clinical trial designs in PAH: shifting from functional measurements to long-term clinical outcomes.

  2014cites this paper
• Endpoints in PAH clinical trials in the era of combination therapy: how do we decide whether something is working without going bankrupt?

  2014cites this paper
• Macitentan , a novel ERA : metabolism and drug interactions

  2014cites this paper
• Riociguat for the treatment of pulmonary arterial hypertension.

  2013cites this paper
• From Short-Term Benefits to Long-Term Outcomes: The Evolution of Clinical Trials in Pulmonary Arterial Hypertension

  2013cites this paper
• Prostanoid therapy for pulmonary arterial hypertension: a meta-analysis of survival outcomes

  2013cites this paper
• Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis.

  2013cites this paper
• Updating clinical endpoint definitions

  2013cites this paper
• Macitentan and morbidity and mortality in pulmonary arterial hypertension.

  2013cites this paper
• Mechanics and function of the pulmonary vasculature: implications for pulmonary vascular disease and right ventricular function.

  2012cites this paper
• Endpoints for clinical trials of sarcoidosis.

  2012cites this paper
• Mechanics and Function of the Pulmonary Vasculature: Implications for Pulmonary Vascular Disease and Right Ventricular Function.

  2012cites this paper
• Perspective on the optimal endpoints for pulmonary arterial hypertension trials

  2010cites this paper
• Vascular Health and Risk Management Dovepress Macitentan for the Treatment of Pulmonary Arterial Hypertension the Endothelins and the Endothelin Receptors

  year unknowncites this paper